The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported
- PMID: 17015493
- PMCID: PMC2910078
- DOI: 10.1542/peds.2006-0588
The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported
Erratum in
- Pediatrics. 2007 Oct;120(4):936
Abstract
Objective: Juvenile GM2 gangliosidosis is a group of inherited neurodegenerative diseases caused by deficiency of lysosomal beta-hexosaminidase resulting in GM2 ganglioside accumulation in brain. The purpose of this study was to delineate the natural history of the condition and identify genotype-phenotype correlations that might be helpful in predicting the course of the disease in individual patients.
Methods: A cohort of 21 patients with juvenile GM2 gangliosidosis, 15 with the Tay-Sachs variant and 6 with the Sandhoff variant, was studied prospectively in 2 centers. Our experience was compared with previously published reports on 134 patients. Information about clinical features, beta-hexosaminidase enzyme activity, and mutation analysis was collected.
Results: In our cohort of patients, the mean (+/-SD) age of onset of symptoms was 5.3 +/- 4.1 years, with a mean follow-up time of 8.4 years. The most common symptoms at onset were gait disturbances (66.7%), incoordination (52.4%), speech problems (28.6%), and developmental delay (28.6%). The age of onset of gait disturbances was 7.1 +/- 5.6 years. The mean time for progression to becoming wheelchair-bound was 6.2 +/- 5.5 years. The mean age of onset of speech problems was 7.0 +/- 5.6 years, with a mean time of progression to anarthria of 5.6 +/- 5.3 years. Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease. Psychiatric disturbances and neuropathy were more prevalent in patients with the Sandhoff variant than in those with the Tay-Sachs variant. However, dysphagia, sphincter incontinence, and sleep problems occurred earlier in those with the Tay-Sachs variant. Cerebellar atrophy was the most common finding on brain MRI (52.9%). The median survival time among the studied and reviewed patients was 14.5 years. The genotype-phenotype correlation revealed that in patients with the Tay-Sachs variant, the presence of R178H and R499H mutations was predictive of an early onset and rapidly progressive course. The presence of either G269S or W474C mutations was associated with a later onset of symptoms along with a more slowly progressive disease course.
Conclusions: Juvenile GM2 gangliosidosis is clinically heterogeneous, not only in terms of age of onset and clinical features but also with regard to the course of the disease. In general, the earlier the onset of symptoms, the more rapidly the disease progresses. The Tay-Sachs and Sandhoff variants differed somewhat in the frequency of specific clinical characteristics. Speech deterioration progressed more rapidly than gait abnormalities in both the Tay-Sachs variant and Sandhoff variant groups. Among patients with the Tay-Sachs variant, the HEXA genotype showed a significant correlation with the clinical course.
Figures




Similar articles
-
HEXA Disorders.1999 Mar 11 [updated 2020 Oct 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 1999 Mar 11 [updated 2020 Oct 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301397 Free Books & Documents. Review.
-
Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases.Orphanet J Rare Dis. 2020 Apr 15;15(1):92. doi: 10.1186/s13023-020-01354-3. Orphanet J Rare Dis. 2020. PMID: 32295606 Free PMC article.
-
Plasma GM2 ganglioside potential biomarker for diagnosis, prognosis and disease monitoring of GM2-Gangliosidosis.Mol Genet Metab. 2023 Feb;138(2):106983. doi: 10.1016/j.ymgme.2022.106983. Epub 2022 Dec 26. Mol Genet Metab. 2023. PMID: 36709536
-
Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study.Mol Genet Metab. 2018 Feb;123(2):97-104. doi: 10.1016/j.ymgme.2017.12.432. Epub 2017 Dec 20. Mol Genet Metab. 2018. PMID: 29352662 Free PMC article.
-
[Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].Yakugaku Zasshi. 2013;133(2):269-74. doi: 10.1248/yakushi.12-00199. Yakugaku Zasshi. 2013. PMID: 23370522 Review. Japanese.
Cited by
-
Zebra-Sphinx: Modeling Sphingolipidoses in Zebrafish.Int J Mol Sci. 2023 Mar 1;24(5):4747. doi: 10.3390/ijms24054747. Int J Mol Sci. 2023. PMID: 36902174 Free PMC article. Review.
-
Therapeutic Strategies For Tay-Sachs Disease.Front Pharmacol. 2022 Jul 5;13:906647. doi: 10.3389/fphar.2022.906647. eCollection 2022. Front Pharmacol. 2022. PMID: 35865957 Free PMC article. Review.
-
Beneficial Effects of Acetyl-DL-Leucine (ADLL) in a Mouse Model of Sandhoff Disease.J Clin Med. 2020 Apr 8;9(4):1050. doi: 10.3390/jcm9041050. J Clin Med. 2020. PMID: 32276303 Free PMC article.
-
Intracerebroventricular administration of a modified hexosaminidase ameliorates late-stage neurodegeneration in a GM2 mouse model.PLoS One. 2025 Jan 3;20(1):e0315005. doi: 10.1371/journal.pone.0315005. eCollection 2025. PLoS One. 2025. PMID: 39752451 Free PMC article.
-
Juvenile-onset motor neuron disease caused by novel mutations in β-hexosaminidase.Mol Genet Metab. 2013 Jan;108(1):65-9. doi: 10.1016/j.ymgme.2012.10.023. Epub 2012 Nov 2. Mol Genet Metab. 2013. PMID: 23158871 Free PMC article.
References
-
- Mahuran DJ. Biochemical consequences of mutations causing the GM2 gangliosidoses. Biochim Biophys Acta. 1999;1455:105–138. - PubMed
-
- Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–254. - PubMed
-
- Kaback MM. Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur J Pediatr. 2000;159(suppl 3):S192–S195. - PubMed
-
- Kaback MM, Zeiger RS, Reynolds LW, Sonneborn M. Approaches to the control and prevention of Tay-Sachs disease. Prog Med Genet. 1974;10:103–134. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical